Organon Acquires Forendo Pharma

Partners Group Acquires Majority Stake in Forefront Dermatology from OMERS Private Equity

February 10, 2022

Healthcare Services

Partners Group has signed an agreement to acquire OMERS Private Equity's interest in Forefront Dermatology, the largest physician-led dermatology group in the U.S. Forefront's physicians and executive team — and OMERS — will remain minority investors as Partners Group becomes the lead sponsor to support continued geographic expansion and growth; the deal is expected to close in early Q2 2022.

Organon Acquires Alydia Health

June 16, 2021

Medical Devices

Organon completed its acquisition of Alydia Health, a commercial-stage medical device company focused on preventing postpartum hemorrhage, for total consideration of $240 million (including up to $25 million in contingent milestones). The deal expands Organon’s portfolio into medical devices and leverages its global commercial footprint to broaden access to Alydia’s Jada System for maternal hemorrhage worldwide.

Organon Acquires U.S. Rights to TOFIDENCE (tocilizumab-bavi) from Biogen

April 1, 2025

Pharmaceuticals

Organon has acquired regulatory and commercial rights in the United States for TOFIDENCE (tocilizumab-bavi), a biosimilar to Actemra, from Biogen. The deal includes an upfront payment to Biogen and Organon will assume tiered royalty and milestone obligations while Bio‑Thera Solutions will retain manufacturing rights for the U.S. market.

Symeres Acquires Organix Inc.

April 26, 2022

Biotechnology

Symeres, a European drug discovery CRO/CDMO backed by Keensight Capital, has acquired Organix Inc., a Woburn, Massachusetts-based organic chemistry services provider specializing in lipids. The deal gives Symeres a strategic US foothold and expands its capabilities into the fast-growing lipids market supporting mRNA therapeutics and vaccines; Organix generates over $10 million in revenue and has roughly 45 employees.

Bayer Acquires UK Biotech KaNDy Therapeutics Ltd.

August 11, 2020

Biotechnology

Bayer has agreed to acquire UK-based clinical-stage biotech KaNDy Therapeutics Ltd. for an upfront $425 million with up to $450 million in additional milestone payments, expanding Bayer's women's healthcare drug development pipeline—specifically the investigational non-hormonal compound NT-814 for menopausal vasomotor symptoms. The acquisition, subject to customary conditions, was announced in August 2020 and is expected to close in September 2020.

Adare Pharma Solutions Acquires Frontida BioPharm

December 1, 2021

Pharmaceuticals

Adare Pharma Solutions, a PE-backed contract development and manufacturing organization (CDMO), has acquired Frontida BioPharm, a vertically integrated CDMO focused on oral formulations. The deal expands Adare’s capabilities—including high-potency compound handling and packaging services—and increases its manufacturing footprint; Adare is backed by Thomas H. Lee Partners and Frazier Healthcare Partners.